Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Puretech Health Plc (PRTC.LN)

Puretech Health Plc (PRTC.LN)
138.800 -3.200 (-2.25%) 04/03/25 [LSE]
137.200 x 1,551 150.000 x 2,840
Realtime by (Cboe BZX)
137.200 x 1,551 150.000 x 2,840
Realtime - - (-) -
News & Headlines for Thu, Apr 3rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted today that its Founded Entity, Akili, Inc. (Nasdaq: AKLI) (“Akili”),...

PRTC : 19.06 (+0.05%)
PRTC.LN : 138.800 (-2.25%)
AKLI : 0.4320 (-0.62%)
PureTech Announces Annual Results for Year Ended December 31, 2022

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter...

PRTC : 19.06 (+0.05%)
PRTC.LN : 138.800 (-2.25%)
BIIB : 131.82 (+0.38%)
KRTX : 329.83 (+0.03%)
VOR : 0.5912 (-6.75%)
AKLI : 0.4320 (-0.62%)
PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences , a clinical-stage...

PRTC : 19.06 (+0.05%)
PRTC.LN : 138.800 (-2.25%)
PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage...

PRTC : 19.06 (+0.05%)
PRTC.LN : 138.800 (-2.25%)
PureTech Health: Notice of Results

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its annual report and financial results on Friday, April 28, 2023, at 2:00 AM EDT/ 7:00 AM BST. The report...

PRTC : 19.06 (+0.05%)
PRTC.LN : 138.800 (-2.25%)
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, and Royalty...

PRTC : 19.06 (+0.05%)
PRTC.LN : 138.800 (-2.25%)
RPRX : 31.84 (+1.79%)
PureTech to Present at the Barclays Global Healthcare Conference

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced...

PRTC : 19.06 (+0.05%)
PRTC.LN : 138.800 (-2.25%)
PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Sonde Health , a health technology...

PRTC : 19.06 (+0.05%)
PRTC.LN : 138.800 (-2.25%)
PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced...

PRTC : 19.06 (+0.05%)
PRTC.LN : 138.800 (-2.25%)
PureTech to Present at the SVB Securities Global Biopharma Conference

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced...

PRTC : 19.06 (+0.05%)
PRTC.LN : 138.800 (-2.25%)

Barchart Exclusives

Dear Tesla Stock Fans, DOGE Reprieve Could Finally Be Coming as Soon as May 2025
Elon Musk could reportedly part ways from DOGE by the end of May. Wedbush analyst Dan Ives says it is good news for TSLA stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades